Sonesitatug vedotin

Phase 2Antibody–drug conjugate

AstraZeneca

Sonesitatug vedotin is one of 31 small molecule programs targeting Stomach Neoplasms. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stomach NeoplasmsRecruiting

Gastroesophageal AdenocarcinomaRecruiting

Stomach NeoplasmsPhase 2

Recruiting

Gastroesophageal AdenocarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

29 competitors in Gastroesophageal Adenocarcinoma

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

2 2

Zaniducla

Jazz Pharmaceuticals

Phase 2

3 3

Cyramza

Eli Lilly

Phase 2

2 4

Eloxatin

Teva

Phase 2

2 5

Taxol

Teva

Phase 2

2 6

Keytruda

Merck & Co.

Phase 2

2 7

Imfinzi

AstraZeneca

Phase 2

1 8

Opdivo

Bristol-Myers Squibb

Phase 2

1 9

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 10

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Stomach Neoplasms

NCT06630130

Q3 2029

Phase 2Recruiting

Gastroesophageal Adenocarcinoma

NCT07069712

Q4 2031

Phase 3Recruiting

Gastric Cancer

NCT07431281

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07431281·2,130 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07069712·100 enrolled

Stomach Neoplasms1 trial

A Phase II Platform Trial of Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (Neo-VIKTORY)

Recruiting·JJeeyun Lee·Phase 2·NCT06630130·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Sonesitatug vedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sonesitatug vedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sonesitatug vedotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Sonesitatug vedotin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2029

Q4 2031

Trials by Indication[1]

Gastric Cancer1 trial

Gastroesophageal Adenocarcinoma1 trial

Stomach Neoplasms1 trial

References

Drug Info

Quick Facts

Related News